laboratory research
Latest
ALBA webinar series - Breaking down the ivory tower: Ep. 2 Philip Haydon
With this webinar series, the ALBA Disability & Accessibility Working Group aims to bring down the ivory tower of ableism among the brain research community, one extraordinary neuroscientist at a time. These webinars give a platform to scientists with disabilities across the globe and neuroscience disciplines, while reflecting on how to promote inclusive working environments and accessibility to research. For this 2nd episode, Prof. Philip Haydon (Tufts University School of Medicine, Boston, USA) will talk about his research and experience. Prof. Philip runs an active laboratory researching a multitude of neurological disorders (including epilepsy). He is also President of Sail For Epilepsy. His mission is to inspire people with epilepsy, raise funds to support research for a cure, promote awareness of epilepsy and educate the public.
Ebselen: a lithium-mimetic without lithium side-effects?
Development of new medications for mental health conditions is a pressing need given the high proportion of people not responding to available treatments. We hope that presenting ebselen to a wider audience will inspire further studies on this promising agent with a benign side-effects profile. Laboratory research, animal research and human studies suggest that ebselen shares many features with the mood stabilising drug lithium, creating a promise of a drug that would have a similar clinical effect but without lithium’s troublesome side-effect profile and toxicity. Both drugs have a common biological target, inositol monophosphatase, whose inhibition is thought key to lithium’s therapeutic effect. Both drugs have neuroprotective action and reduce oxidative stress. In animal studies, ebselen affected neurotransmitters involved in the development of mental health symptoms, and in particular, produced effects of serotonin function very similar to lithium. Both ebselen and lithium share behavioural effects: antidepressant-like effects in rodent models of depression and decrease in behavioural impulsivity, a property associated with lithium's anti-suicidal action. Human neuropsychological studies support an antidepressant profile for ebselen based on its positive impact on emotional processing and reward seeking. Our group currently is exploring ebselen’s effects in patients with mood disorders. A completed ‘add-on’ clinical trial in mania showed ebselen’s superiority over placebo after three weeks of treatment. Our ongoing experimental research explores ebselen’s antidepressant profile in patients with treatment resistant depression. If successful, this will lead to a clinical trial of ebselen as an antidepressant augmentation agent, similar to lithium.
Neuroscience in the mud: interplay between lab and field research for understanding animal behavior
Investigations of the neurophysiological processes underlying animal behaviors are almost exclusively done inside the laboratory, typically using few animal models born and reared under artificially stabilized conditions. Yet, animals living in the wild have to cope with much complex and variable environments. Thus, while the laboratory provides the technical possibilities for physiological research, the field offers a more realistic perspective about the animal´s behavioral abilities. We study neural circuits underlying the visually guided prey and predator behaviors in a semiterrestrial crab. By combining lab and field experiments we have, for example, found that the level of predation risk experienced by the animals in the wild affects the responsiveness of identified neurons involved in the animal escape response. Using this and other results from my lab I will illustrate and discuss the importance of complementing lab with field studies in wild animals for understanding the neural mechanisms subserving behavior.
laboratory research coverage
3 items